News & Events
< Back to News Overview
Sunshine Heart Profiled at Washington DC AdvaMed 2007 MedTech Conference
08 / 10 / 2007
Don Rohrbaugh, Chief Executive Officer of Sunshine Heart, Inc. (ASX: SHC) was among a select number of medical technology industry leaders invited to present at the prestigious AdvaMed 2007 MedTech Conference held in Washington DC, USA.
The AdvaMed 2007 MedTech Conference which is the showcase for the largest and most influential medical technology association in the world, was attended by more than 800 senior level executives representing more than 500 companies from 30 US States and 15 countries.
Mr Rohrbaughs presentation for Sunshine Heart which outlined the unique characteristics and market advantages of the Companys C-PulseT heart assist device, was well received by the attendees.
"I appreciated the opportunity to share the Sunshine Heart story with business leaders, policymakers, news media and financiers from around the world," said Mr Rohrbaugh. "With our pending US Feasibility study, we will be making history as the first company in the world to trial a non-blood-contacting heart assist device, as we address the unmet clinical needs of thousands of patients with moderate heart failure."
A copy of Mr Rohrbaughs AdvaMed 2007 MedTech presentation is attached. Additional details about the C-PulseT system and related information is available on the companys website www.sunshineheart.com
The AdvaMed 2007 MedTech Conference which is the showcase for the largest and most influential medical technology association in the world, was attended by more than 800 senior level executives representing more than 500 companies from 30 US States and 15 countries.
Mr Rohrbaughs presentation for Sunshine Heart which outlined the unique characteristics and market advantages of the Companys C-PulseT heart assist device, was well received by the attendees.
"I appreciated the opportunity to share the Sunshine Heart story with business leaders, policymakers, news media and financiers from around the world," said Mr Rohrbaugh. "With our pending US Feasibility study, we will be making history as the first company in the world to trial a non-blood-contacting heart assist device, as we address the unmet clinical needs of thousands of patients with moderate heart failure."
A copy of Mr Rohrbaughs AdvaMed 2007 MedTech presentation is attached. Additional details about the C-PulseT system and related information is available on the companys website www.sunshineheart.com